U.S. Markets closed

Ablynx NV (ABLX.BR)

Brussels - Brussels Delayed Price. Currency in EUR
Add to watchlist
11.15+0.05 (+0.45%)
At close: 5:35PM CEST

Ablynx NV

Technologiepark 21
Ghent 9052
32 9 262 00 00

Full Time Employees389

Key Executives

Dr. Edwin Moses Ph.D.Chief Exec. Officer and DirectorN/AN/A63
Mr. Wim OttevaereChief Financial OfficerN/AN/A61
Mr. Antonin Rollet De Fougerolles Ph.D.Chief Scientific OfficerN/AN/A52
Marieke Vermeersch MSc, MBADirector of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Gerrit Franciscus LandoltVP of IP & LegalN/AN/A53
Amounts are as of December 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-vWF Nanobody that is in Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, an anti-RSV Nanobody, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus (RSV) infection; and Vobarilizumab, an anti-IL-6R Nanobody that is in Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as auto-immune disorders; ozoralizumab, which is in a Phase IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone related disorders, including osteoporosis and bone metastases, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaborations with AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk, and Taisho Pharmaceuticals. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.

Corporate Governance

Ablynx NV’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.